NAD+: the longevity molecule that just got its biggest scientific endorsement yet

If you’ve spent any time in longevity or peptide research circles, you’ve heard of NAD+. You’ve probably also heard conflicting claims about whether it actually does anything meaningful.

A paper published in Nature Aging this week may not settle the debate entirely, but it shifts the weight of scientific opinion in a significant direction.

More than 25 scientists, including clinicians and leading experts in aging biology and metabolism from the University of Oslo, Akershus University Hospital, and international institutions, have published a coordinated expert review on nicotinamide adenine dinucleotide (NAD+). Their conclusion: raising NAD+ levels holds real promise for slowing age-related decline and protecting against conditions like Alzheimer’s and Parkinson’s disease.

This isn’t a single lab’s findings. It’s a scientific consensus statement. That matters.

What is NAD+?

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell. It plays a central role in three processes that are fundamental to health:

Energy production. NAD+ is essential for cellular respiration, the process by which mitochondria convert nutrients into ATP, the energy currency cells run on. Without adequate NAD+, mitochondria become less efficient.

DNA repair. A class of enzymes called PARPs use NAD+ to detect and repair DNA damage. As cells accumulate damage over a lifetime, the demand for NAD+ in repair increases even as supply declines.

Cellular regulation. Sirtuins, a family of proteins strongly associated with longevity in research, depend on NAD+ as a cofactor. They regulate gene expression, inflammation, and stress responses. No NAD+, no sirtuin activity.

The age-related decline

The core finding driving NAD+ research is stark: tissue concentrations of NAD+ drop by approximately 50% between young adulthood and later decades. This isn’t a marginal change. It’s a fundamental shift in cellular function across the whole body.

This decline has been documented in muscle, brain, liver, and blood across multiple studies and species. It correlates, though not always causally (the review authors are careful to note this), with the standard markers of biological aging: cognitive decline, reduced muscle strength, metabolic dysfunction, and elevated disease risk.

The question the Nature Aging review addresses is whether that decline is something we can reverse, slow, or work around.

NMN and NR: the two main approaches

The most studied strategies for raising NAD+ levels involve supplementing with precursor molecules, compounds the body can convert into NAD+. Two have received the most clinical attention:

NMN (nicotinamide mononucleotide) is a direct precursor in the NAD+ biosynthesis pathway. It can be absorbed via the small intestine and converted to NAD+ in tissues. Multiple clinical trials, including studies at Keio University in Japan and Washington University in St. Louis, have shown NMN supplementation raises NAD+ levels in humans.

NR (nicotinamide riboside) is another precursor, one step further back in the pathway. It’s been studied in trials covering conditions from aging to heart failure. ChromaDex’s Tru Niagen (NR supplement) was one of the first commercially available NAD+ precursors with meaningful clinical data behind it.

Both are classified as vitamins (variants of vitamin B3) and have reasonable short-term safety profiles in trials to date.

What the clinical trials show

The Nature Aging review synthesises years of laboratory and clinical research. The authors report that early trial findings are promising across three main outcome categories:

Cognitive function: Some trials report improvements in memory and cognitive performance in older adults supplementing with NMN or NR, though sample sizes remain small and results are not uniform.

Physical performance: Studies show improvements in measures of physical movement, endurance, and muscle function, relevant given the established link between muscle decline and all-cause mortality in aging.

Metabolic health: Improvements in insulin sensitivity and markers of metabolic function have been reported across several trials, consistent with the role of NAD+ in mitochondrial efficiency and energy metabolism.

The authors are careful to note that the evidence base is still developing. Most trials are short. Individual responses vary substantially. Optimal dosing remains unclear.

Their call: larger, longer, better-powered trials, including in patient populations with age-related diseases, to confirm whether the preclinical promise translates to clinically meaningful outcomes.

The neurodegeneration connection

One of the more compelling dimensions of the review is its focus on Alzheimer’s and Parkinson’s disease.

Both conditions involve significant mitochondrial dysfunction. In Alzheimer’s, impaired energy metabolism in neurons is one of the earliest observable changes, often preceding visible plaques and tangles. In Parkinson’s, mitochondrial dysfunction in dopaminergic neurons is a core feature of the disease mechanism.

The NAD+ angle is this: if mitochondrial inefficiency and compromised DNA repair are among the drivers of neuronal vulnerability, then addressing the NAD+ decline that underlies both processes is a logical therapeutic target.

This is still largely preclinical reasoning in the context of neurodegenerative disease specifically. The review calls for the clinical trials to confirm it. But the mechanistic logic is strong, and several trials targeting NAD+ in Alzheimer’s patients are now underway.

Why this review matters

There’s a difference between individual studies pointing in an interesting direction and a coordinated consensus from 25+ senior scientists spanning multiple institutions and clinical disciplines.

Nature Aging is a high-impact journal. It doesn’t publish opinion pieces; it publishes peer-reviewed science. The fact that this many researchers with this range of expertise chose to co-author a consensus review on NAD+ signals something: the evidence has matured to the point where a field-wide statement was considered warranted.

It doesn’t mean NAD+ supplementation is validated treatment for any disease. But it does mean the scientific community regards the question as serious, the early evidence as encouraging, and the need for robust clinical trials as urgent.

Where NAD+ sits in longevity research

For those following peptide and longevity research more broadly, NAD+ occupies an interesting position.

Unlike many research peptides, NMN and NR are commercially available supplement-grade compounds with growing consumer markets. The science is accessible. The regulatory path is clearer than for injectable peptides.

But the mechanism they target, mitochondrial function and NAD+ metabolism, overlaps significantly with the territory of research peptides like Humanin (a mitochondrial-derived peptide) and SS-31/Elamipretide (which directly protects mitochondrial membrane integrity).

These aren’t competing approaches. They’re converging on the same problem from different angles: how do you maintain mitochondrial function as the body ages? NAD+ precursors, mitochondrial peptides, and caloric restriction mimetics like rapamycin are all circling the same core biology.

The Nature Aging review adds weight to the idea that this biology is genuinely important, and that 2026 is a year when the evidence base is accelerating fast enough to demand serious attention.

The bottom line

NAD+ levels decline ~50% with age. That decline maps onto mitochondrial dysfunction, DNA repair impairment, and reduced sirtuin activity, all hallmarks of biological aging.

NMN and NR can raise NAD+ levels in humans. Early clinical trials are promising. The field needs bigger, longer trials with harder endpoints to confirm clinical significance.

25+ scientists just published a consensus in Nature Aging saying this is a serious therapeutic target worth pursuing with rigour. That’s the clearest signal yet that NAD+ research has moved past curiosity into something the field is ready to test properly.

Review published in Nature Aging, March 2026. Coverage via ScienceDaily.